Document is current
Any future updates will be listed below
-
Authors
Ren, Qing-Wen
Teng, Tiew-Hwa Katherine https://orcid.org/0000-0002-8431-9961
Ouwerkerk, Wouter https://orcid.org/0000-0002-2000-9358
Tse, Yi-Kei
Tsang, Christopher Tze Wei https://orcid.org/0000-0003-3394-6604
Wu, Mei-Zhen
Tse, Hung-Fat
Voors, Adriaan A.
Tromp, Jasper
Lam, Carolyn S. P. https://orcid.org/0000-0003-1903-0018
Yiu, Kai-Hang https://orcid.org/0000-0003-2145-3108
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 28 January 2025
First Online: 6 February 2025
Competing interests
: C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific and Roche Diagnostics. has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., Us2.ai, Janssen Research & Development LLC, Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi and WebMD Global LLC; and serves as co-founder & non-executive director of Us2.ai. JT received speaker or consultancy fees from Roche Diagnostics, Daiichi Sankyo, Boehringer Ingelheim, and Us.2ai. He is supported by the National University of Singapore start-up grant and a Ministry of Education tier 1 grant. The remaining authors declare no competing interests.
